Stocktoria
ENANTA PHARMACEUTICALS INC ENTA
ENANTA PHARMACEUTICALS INC (ENTA) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $65.3M at a -125.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.555 |
| Retained earnings / assets | -1.442 |
| EBIT / assets | -0.304 |
| Equity / liabilities | 0.3 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ENTA | ENANTA PHARMACEUTICALS INC | 4/9 | -2.79 | — | -3.4% |
| AYTU | AYTU BIOPHARMA, INC | 4/9 | -8.14 | — | +1.8% |
| SPRO | Spero Therapeutics, Inc. | 4/9 | -8.9 | 15.3 | +39.2% |
| FBIO | Fortress Biotech, Inc. | 4/9 | -12.29 | 13.5 | +9.7% |
| KURA | Kura Oncology, Inc. | 2/9 | -2.37 | — | +25.2% |
| NUVB | Nuvation Bio Inc. | 3/9 | -2.01 | — | — |
| TNGX | Tango Therapeutics, Inc. | 3/9 | 5.58 | — | +48.3% |
About ENANTA PHARMACEUTICALS INC
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
FAQ
Is ENTA financially healthy?
ENANTA PHARMACEUTICALS INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ENTA pay a dividend?
No, ENANTA PHARMACEUTICALS INC does not currently pay a dividend.
How profitable is ENTA?
In FY2025, ENANTA PHARMACEUTICALS INC had a net margin of -125.4% and a return on equity of -126.5%.
Is ENTA overvalued or undervalued?
ENANTA PHARMACEUTICALS INC trades at about 6.1× trailing earnings — below its 10-year norm (10-year range 6.9×–54.6×, median 23.9×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ENTA?
The average Wall-Street price target for ENANTA PHARMACEUTICALS INC is $20.14, about 49.2% above the recent price, from 7 analysts (consensus: strong buy).
Is ENTA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ENANTA PHARMACEUTICALS INC: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.